Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Kolkata: After a successful pilot project, Bengal govt is set to roll out a triple elimination programme for HIV, hepatitis B ...

Aside from recent outbreaks of polio in war-torn regions of the world, the deadly virus is close to being eradicated, thanks ...

There are now a number of other drugs in the same class in different stages of development, which have been shown to be even more potent inhibitors of hepatitis B replication. The large experience ...

Durham-based Atsena Therapeutics has raised $150 million to advance gene therapies for preventing or reversing types of ...

Antiviral treatments strive to block a virus or halt its replication ... 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective ...

Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although ...

The global antiviral drugs market is poised for steady expansion, projected to reach a valuation of USD 89.68 billion by 2033, up from USD 61.42 billion in 2023, growing at a Comp ...

Data for the replication cohort were extracted from the biobank ... Patients with a diagnosis of “Hepatitis C virus infection,” “Chronic hepatitis C,” “Hepatitis B virus infection,” or “Chronic ...

The hepatitis B virus (HBV) is the cause of chronic hepatitis B (CHB) and despite the availability of effective prophylactic vaccines and treatments that efficiently suppress viral replication, HBV ...